Group 1 - The core point of the article is that Weihong Co., Ltd. held its 18th meeting of the 5th board of directors on October 23, 2025, to review the proposal for the company's Q3 2025 report [1] - For the first half of 2025, Weihong Co., Ltd. reported that its revenue composition was 99.14% from engraving and milling, while other businesses accounted for 0.86% [1] - As of the report, Weihong Co., Ltd. has a market capitalization of 3.1 billion yuan [1] Group 2 - The article also highlights that the Chinese innovative drug sector has sold overseas authorizations worth 80 billion USD this year, indicating a hot secondary market in biomedicine [1] - A conversation with Lu Gang, a partner at Chuangdong Investment, reveals that while the secondary market is thriving, the primary market is facing challenges in fundraising [1]